Immunotherapy with T cells expressing the chimeric antigen receptor (CAR) specific for the
CD19 antigen (CD19. CAR-Ts) is a very effective treatment in B cell lymphoid malignancies …

Highlights•The inducible caspase-9 safety switch is designed to increase the safety of
immunotherapy.•It is based on the fusion of human proteins and non-immunogenicity.• …

Background Approximately fifty percent of patients with acute myeloid leukemia can be
cured with current therapeutic strategies which include, standard dose chemotherapy for …

Introduction CAR T cells have generated great excitement due to their remarkable clinical
response rates in selected hematologic malignancies. However, these engineered immune …

Lentiviral vector (LV)–based gene therapy holds promise for a broad range of diseases.
Analyzing more than 280,000 vector integration sites (VISs) in 273 samples from 10 patients …

Gene-modified cellular therapies carry inherent risks of severe and potentially fatal adverse
events, including the expansion of alloreactive cells or malignant transformation due to …

Activation of the inducible caspase 9 (iC9) safety gene by a dimerizing drug (chemical
inducer of dimerization (CID) AP1903) effectively resolves the symptoms and signs of graft …

Delayed immune reconstitution and the consequently high rates of leukemia relapse and
infectious complications are the main limitations of haploidentical hematopoietic stem cell …

T cells engineered to express chimeric antigen receptors (CARs) with specificity toward
tumor cells have led to promising outcomes in patients with hematological malignancies …

Hematopoietic stem cell transplantation is a potent form of immunotherapy, potentially life-
saving for many malignant hematologic diseases. However, donor lymphocytes infused with …